CancerDrs Find care

Prostate Cancer clinical trials in Alabama

7 actively recruiting prostate cancer trials at 5 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …

Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Alabama:
  • Clearview Cancer Institute (Crestwood) — Huntsville, Alabama
  • Clearview Cancer Institute — Huntsville, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

Sponsor: Amgen
NCT ID: NCT06691984
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…

Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Alabama:
  • Dothan Hematology & Oncology — Dothan, Alabama
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Alabama:
  • University of Alabama at Birmingham Hospital — Birmingham, Alabama
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20